According to the Zhixuan Finance App, Giant Bio (02367) rose more than 3% and at the time of publication, it rose 3.07%, to HKD 45.30, with a turnover of HKD 14.87 million.

On the news front, Citigroup released a research report stating that Giant Bio will be given a "buy" rating for the first time and will be a major beneficiary of the structural trend of "skin care and medical cosmetics". It is expected that net income will increase by 35% in the first half of 2024, and the compound annual growth rate from 2023 to 2026 will reach 26%. The report pointed out that although overall demand for cosmetics has slowed down, skin care and beauty products are expected to continue to thrive due to the growing demand from young consumers.

Previously, according to the official WeChat account of Giant Bio, the 618 report showed that the full cycle of 618 in 2024 (May 15 to June 20) could have a year-on-year increase of more than 60% in online GMV for Kafu Mei, and a year-on-year increase of more than 100% in online GMV for Keli Jin. Both core brands of the company achieved contrarian high growth. Citic Securities released a research report stating that the sales of recombined collagen products were excellent, and Kafu Mei, Keli Jin, Wei Yimei and other brands have been performing well since this year. Domestic and international companies are accelerating their layout in the field of recombined collagen, and are continuing to launch new products.